Search results
Results from the WOW.Com Content Network
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. [ 6 ] [ 7 ] [ 10 ] It is also used to treat adults with heart failure and chronic kidney disease .
Dapagliflozin, (brand name Forxiga), was approved by the EU in 2012, the first SGLT2 inhibitor approved anywhere. [28] It was approved for use in the United States under the brand name Farxiga in January 2014. [29] Empagliflozin, approved in the United States in August 2014, under the brand name Jardiance by Boehringer Ingelheim. [30]
Regarding incidence, cohort longitudinal studies (studies where a disease-free population is followed over the years) provide rates between 10 and 15 per thousand person-years for all dementias and 5–8 for AD, [235] [236] which means that half of new dementia cases each year are Alzheimer's disease. Advancing age is a primary risk factor for ...
Through this free service, specialists and master's-level clinicians offer confidential support and information to people living with dementia, caregivers, families and the public. [4] The Association also has free online tools to help people find answers, local resources and support.
Pre-dementia or early-stage dementia (stages 1, 2, and 3). In this initial phase, a person can still live independently and may not exhibit obvious memory loss or have any difficulty completing ...
Design, Dignity, Dementia: dementia-related design and the built environment Collates the progress which has been made in dementia-related design to date, including best practice from pioneers and innovators across multiple environments including in home/domestic settings, day and residential care, hospitals and public buildings and spaces. [38]
CaringBridge allows patients, caregivers, families, and friends to exchange information about a patient's medical condition on an ongoing basis. [3] The websites are designed to become conduits between patients, their families, friends, neighbors, and colleagues. [4]
Vascular dementia is the second-most-common form of dementia after Alzheimer's disease in older adults. [4] The prevalence of the illness is 1.5% in Western countries and approximately 2.2% in Japan.